Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 13/2022

19.07.2022 | Original Article

Long-term test-retest of cerebral [18F]MK-6240 binding and longitudinal evaluation of extracerebral tracer uptake in healthy controls and amnestic MCI patients

verfasst von: Greet Vanderlinden, Nathalie Mertens, Laura Michiels, Robin Lemmens, Michel Koole, Mathieu Vandenbulcke, Koen Van Laere

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 13/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Neurofibrillary tangles (NFTs) in Alzheimer’s disease can be accurately quantified in vivo using [18F]MK-6240 PET. Short-term [18F]MK-6240 test-retest (TRT) is about 6%, but also long-term stability of cerebral uptake is of importance for longitudinal studies. Furthermore, although there is very little cerebral off-target binding, [18F]MK-6240 shows variable extracerebral uptake (ECU) assumed to represent off-target binding to leptomeningeal melanocytes. Here, we examined 6-month TRT of [18F]MK-6240 in healthy controls (HC) and investigated ECU in HC and patients with amnestic mild cognitive impairment (aMCI) with up to 2 years of follow-up. We also explored demographic factors that may be associated to ECU, including age, sex, education, smoking, and disease status.

Methods

A total cohort of 40 HC (57 ± 19 years, 21F/19 M) and 24 aMCI (72 ± 8 years, 14F/10 M) underwent baseline [18F]MK-6240 PET-MR (GE Signa), 90–120 min post injection. [18F]MK-6240 was quantified by standardized uptake value ratios (SUVR) in predefined volumes-of-interest relative to the cerebellar cortex. Ten HC (56 ± 12 years, 8F/2 M) underwent a 6-month follow-up [18F]MK-6240 to assess TRT. Also, 10 aMCI (72 ± 6 years, 5F/5 M) underwent a 2-year follow-up [18F]MK-6240 PET-MR. Longitudinal changes in ECU were assessed in both cohorts. ECU was quantified as the mean SUVR of the skull parcel (FreeSurfer 6.0) that includes the meninges.

Results

The mean gray matter [18F]MK-6240 SUVR TRT and absolute TRT in HC were 1.6 ± 3.4% and 2.4 ± 2.8%, respectively. We found no significant 6-month or 2-year differences in ECU in HC (4.4 ± 20%) and aMCI (7.9 ± 19%), respectively. In the total cohort, ECU was significantly correlated to age (rs =  − 0.48; p < 0.0001), and a multivariate analysis also showed sex differences (higher ECU in women).

Conclusion

[18F]MK-6240 shows excellent 6-month TRT, which confirms its suitability for quantification of longitudinal NFT changes. The ECU of [18F]MK-6240 is variable between subjects, influenced by age and sex, but remains stable within subjects over a 2-year time period.
Literatur
1.
Zurück zum Zitat Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Budd Haeberlein S, et al. NIA-AA Research framework: toward a biological definition of Alzheimer’s disease HHS public access author manuscript. Alzheimers Dement. 2018;14(4):535–62.CrossRef Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Budd Haeberlein S, et al. NIA-AA Research framework: toward a biological definition of Alzheimer’s disease HHS public access author manuscript. Alzheimers Dement. 2018;14(4):535–62.CrossRef
2.
Zurück zum Zitat Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–59.CrossRef Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–59.CrossRef
3.
Zurück zum Zitat Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018;14(4):225–36.CrossRef Villemagne VL, Doré V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018;14(4):225–36.CrossRef
4.
Zurück zum Zitat Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, et al. Tau PET imaging in neurodegenerative tauopathies—still a challenge. Mol Psychiatry. 2019;24(8):1112–34.CrossRef Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, et al. Tau PET imaging in neurodegenerative tauopathies—still a challenge. Mol Psychiatry. 2019;24(8):1112–34.CrossRef
5.
Zurück zum Zitat Lemoine L, Leuzy A, Chiotis K, Rodriguez-Vieitez E, Nordberg A. Tau positron emission tomography imaging in tauopathies: the added hurdle of off-target binding. Alzheimers Dement (Amst). 2018;10:232–6.CrossRef Lemoine L, Leuzy A, Chiotis K, Rodriguez-Vieitez E, Nordberg A. Tau positron emission tomography imaging in tauopathies: the added hurdle of off-target binding. Alzheimers Dement (Amst). 2018;10:232–6.CrossRef
6.
Zurück zum Zitat Lohith TG, Bennacef I, Vandenberghe R, Vandenbulcke M, Salinas CA, Declercq R, et al. Brain imaging of Alzheimer dementia patients and elderly controls with 18 F-MK-6240, a PET tracer targeting neurofibrillary tangles. J Nucl Med. 2019;60:107–14.CrossRef Lohith TG, Bennacef I, Vandenberghe R, Vandenbulcke M, Salinas CA, Declercq R, et al. Brain imaging of Alzheimer dementia patients and elderly controls with 18 F-MK-6240, a PET tracer targeting neurofibrillary tangles. J Nucl Med. 2019;60:107–14.CrossRef
7.
Zurück zum Zitat Gogola A, Minhas DS, Villemagne VL, Cohen AD, Mountz JM, Pascoal TA, et al. Direct comparison of the tau PET tracers [18 F]flortaucipir and [18 F]MK-6240 in human subjects. J Nucl Med. 2022;63(1):108–16.CrossRef Gogola A, Minhas DS, Villemagne VL, Cohen AD, Mountz JM, Pascoal TA, et al. Direct comparison of the tau PET tracers [18 F]flortaucipir and [18 F]MK-6240 in human subjects. J Nucl Med. 2022;63(1):108–16.CrossRef
8.
Zurück zum Zitat Aguero C, Dhaynaut M, Normandin MD, Amaral AC, Guehl NJ, Neelamegam R, et al. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol Commun. 2019;7(1):37.CrossRef Aguero C, Dhaynaut M, Normandin MD, Amaral AC, Guehl NJ, Neelamegam R, et al. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol Commun. 2019;7(1):37.CrossRef
9.
Zurück zum Zitat Betthauser TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE, et al. In vivo characterization and quantification of neurofibrillary tau PET radioligand 18 F-MK-6240 in humans from Alzheimer disease dementia to young controls. J Nucl Med. 2019;60(1):93–9.CrossRef Betthauser TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE, et al. In vivo characterization and quantification of neurofibrillary tau PET radioligand 18 F-MK-6240 in humans from Alzheimer disease dementia to young controls. J Nucl Med. 2019;60(1):93–9.CrossRef
10.
Zurück zum Zitat Guehl NJ, Wooten DW, Yokell DL, Moon SH, Dhaynaut M, Katz S, et al. Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [18 F]MK6240 in human subjects. Eur J Nucl Med Mol Imaging. 2019;46:2099–111.CrossRef Guehl NJ, Wooten DW, Yokell DL, Moon SH, Dhaynaut M, Katz S, et al. Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [18 F]MK6240 in human subjects. Eur J Nucl Med Mol Imaging. 2019;46:2099–111.CrossRef
11.
Zurück zum Zitat Pascoal TA, Shin M, Kang MS, Chamoun M, Chartrand D, Mathotaarachchi S, et al. In vivo quantification of neurofibrillary tangles with [18 F]MK-6240. Alzheimer’s Res Ther. 2018;10(1):74.CrossRef Pascoal TA, Shin M, Kang MS, Chamoun M, Chartrand D, Mathotaarachchi S, et al. In vivo quantification of neurofibrillary tangles with [18 F]MK-6240. Alzheimer’s Res Ther. 2018;10(1):74.CrossRef
12.
Zurück zum Zitat Koole M, Lohith TG, Valentine JL, Bennacef I, Declercq R, Reynders T, et al. Preclinical safety evaluation and human dosimetry of [18 F]MK-6240, a novel PET tracer for imaging neurofibrillary tangles. Mol Imaging Biol. 2020;22(1):173–80.CrossRef Koole M, Lohith TG, Valentine JL, Bennacef I, Declercq R, Reynders T, et al. Preclinical safety evaluation and human dosimetry of [18 F]MK-6240, a novel PET tracer for imaging neurofibrillary tangles. Mol Imaging Biol. 2020;22(1):173–80.CrossRef
13.
Zurück zum Zitat Malarte ML, Nordberg A, Lemoine L. Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer’s disease cases. Eur J Nucl Med Mol Imaging. 2021;48(4):1093–102.CrossRef Malarte ML, Nordberg A, Lemoine L. Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer’s disease cases. Eur J Nucl Med Mol Imaging. 2021;48(4):1093–102.CrossRef
14.
Zurück zum Zitat Hostetler ED, Walji AM, Zeng Z, Miller P, Bennacef I, Salinas C, et al. Preclinical characterization of 18 F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med. 2016;57:1599–606.CrossRef Hostetler ED, Walji AM, Zeng Z, Miller P, Bennacef I, Salinas C, et al. Preclinical characterization of 18 F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med. 2016;57:1599–606.CrossRef
15.
Zurück zum Zitat Vanhaute H, Ceccarini J, Michiels L, Koole M, Sunaert S, Lemmens R, et al. In vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment. Neurology. 2020;95(5):e545–53.CrossRef Vanhaute H, Ceccarini J, Michiels L, Koole M, Sunaert S, Lemmens R, et al. In vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment. Neurology. 2020;95(5):e545–53.CrossRef
16.
Zurück zum Zitat Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020;143(9):2818–30.CrossRef Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020;143(9):2818–30.CrossRef
17.
Zurück zum Zitat Salinas C, Lohith TG, Purohit A, Struyk A, Sur C, Bennacef I, et al. Test–retest characteristic of [18F]MK-6240 quantitative outcomes in cognitively normal adults and subjects with Alzheimer’s disease. J Cereb Blood Flow Metab. 2020;40(11):2179–87.CrossRef Salinas C, Lohith TG, Purohit A, Struyk A, Sur C, Bennacef I, et al. Test–retest characteristic of [18F]MK-6240 quantitative outcomes in cognitively normal adults and subjects with Alzheimer’s disease. J Cereb Blood Flow Metab. 2020;40(11):2179–87.CrossRef
18.
Zurück zum Zitat Smith R, Strandberg O, Leuzy A, Betthauser TJ, Johnson SC, Pereira JB, et al. Sex differences in off-target binding using tau positron emission tomography. NeuroImage Clin. 2021;31:102708.CrossRef Smith R, Strandberg O, Leuzy A, Betthauser TJ, Johnson SC, Pereira JB, et al. Sex differences in off-target binding using tau positron emission tomography. NeuroImage Clin. 2021;31:102708.CrossRef
19.
Zurück zum Zitat Mertens N, Michiels L, Vanderlinden G, Vandenbulcke M, Lemmens R, Van Laere K, et al. Impact of meningeal uptake and partial volume correction techniques on [18 F] MK-6240 binding in aMCI patients and healthy controls. J Cereb Blood Flow Metab. 2022;41(11):1–11. Mertens N, Michiels L, Vanderlinden G, Vandenbulcke M, Lemmens R, Van Laere K, et al. Impact of meningeal uptake and partial volume correction techniques on [18 F] MK-6240 binding in aMCI patients and healthy controls. J Cereb Blood Flow Metab. 2022;41(11):1–11.
20.
Zurück zum Zitat Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011;7(3):270–9.CrossRef Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011;7(3):270–9.CrossRef
21.
Zurück zum Zitat Collier TL, Yokell DL, Livni E, Rice PA, Celen S, Serdons K, et al. cGMP production of the radiopharmaceutical [18 F]MK-6240 for PET imaging of human neurofibrillary tangles. J Label Compd Radiopharm. 2017;60:263–9.CrossRef Collier TL, Yokell DL, Livni E, Rice PA, Celen S, Serdons K, et al. cGMP production of the radiopharmaceutical [18 F]MK-6240 for PET imaging of human neurofibrillary tangles. J Label Compd Radiopharm. 2017;60:263–9.CrossRef
22.
Zurück zum Zitat Schramm G, Koole M, Willekens SMA, Rezaei A, Van Weehaeghe D, Delso G, et al. Regional accuracy of ZTE-based attenuation correction in static [18F]FDG and dynamic [18F]PE2I Brain PET/MR. Front Phys. 2019;7:211.CrossRef Schramm G, Koole M, Willekens SMA, Rezaei A, Van Weehaeghe D, Delso G, et al. Regional accuracy of ZTE-based attenuation correction in static [18F]FDG and dynamic [18F]PE2I Brain PET/MR. Front Phys. 2019;7:211.CrossRef
23.
Zurück zum Zitat Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968–80.CrossRef Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968–80.CrossRef
24.
Zurück zum Zitat Fischl B, van der Kouwe A, Destrieux C, Halgren E, Ségonne F, Salat DH, et al. Automatically parcellating the human cerebral cortex. Cortex. 2004;14:11–22.CrossRef Fischl B, van der Kouwe A, Destrieux C, Halgren E, Ségonne F, Salat DH, et al. Automatically parcellating the human cerebral cortex. Cortex. 2004;14:11–22.CrossRef
25.
Zurück zum Zitat Fischl B, Salat D, Busa E, Albert M, Dieterich M, Haselgrove C. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341–55.CrossRef Fischl B, Salat D, Busa E, Albert M, Dieterich M, Haselgrove C. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341–55.CrossRef
26.
Zurück zum Zitat Cselényi Z, Jönhagen ME, Forsberg A, Halldin C, Schou M, Johnström P, et al. Clinical validation of 18 F-AZD4694, an Amyloid-b-specific PET radioligand. J Nucl Med. 2012;53:415–24.CrossRef Cselényi Z, Jönhagen ME, Forsberg A, Halldin C, Schou M, Johnström P, et al. Clinical validation of 18 F-AZD4694, an Amyloid-b-specific PET radioligand. J Nucl Med. 2012;53:415–24.CrossRef
27.
Zurück zum Zitat Timmers T, Ossenkoppele R, Visser D, Tuncel H, Wolters EE, Cj Verfaillie S, et al. Test-retest repeatability of [18F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals. J Cereb Blood Flow Metab. 2020;40(12):2464–74.CrossRef Timmers T, Ossenkoppele R, Visser D, Tuncel H, Wolters EE, Cj Verfaillie S, et al. Test-retest repeatability of [18F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals. J Cereb Blood Flow Metab. 2020;40(12):2464–74.CrossRef
28.
Zurück zum Zitat Gudjohnsen SAH, Atacho DAM, Gesbert F, Raposo G, Hurbain I, Larue L, et al. Meningeal melanocytes in the mouse: distribution and dependence on Mitf. Front Neuroanat. 2015;9(149). Gudjohnsen SAH, Atacho DAM, Gesbert F, Raposo G, Hurbain I, Larue L, et al. Meningeal melanocytes in the mouse: distribution and dependence on Mitf. Front Neuroanat. 2015;9(149).
29.
Zurück zum Zitat May H, Peled N, Dar G, Abbas J, Hershkovitz I. Hyperostosis frontalis interna: what does it tell us about our health? Am J Hum Biol. 2011;23(3):392–7.CrossRef May H, Peled N, Dar G, Abbas J, Hershkovitz I. Hyperostosis frontalis interna: what does it tell us about our health? Am J Hum Biol. 2011;23(3):392–7.CrossRef
30.
Zurück zum Zitat Murugan NA, Chiotis K, Rodriguez-Vieitez E, Lemoine L, Ågren H, Nordberg A. Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. Eur J Nucl Med Mol Imaging. 2019;46:1369–82.CrossRef Murugan NA, Chiotis K, Rodriguez-Vieitez E, Lemoine L, Ågren H, Nordberg A. Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. Eur J Nucl Med Mol Imaging. 2019;46:1369–82.CrossRef
31.
Zurück zum Zitat Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 1996;379(6567):733–6.CrossRef Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 1996;379(6567):733–6.CrossRef
32.
Zurück zum Zitat Kolinger GD, Vállez García D, Lohith TG, Hostetler ED, Sur C, Struyk A, et al. A dual-time-window protocol to reduce acquisition time of dynamic tau PET imaging using [18F]MK-6240. EJNMMI Res. 2021;11(1):49.CrossRef Kolinger GD, Vállez García D, Lohith TG, Hostetler ED, Sur C, Struyk A, et al. A dual-time-window protocol to reduce acquisition time of dynamic tau PET imaging using [18F]MK-6240. EJNMMI Res. 2021;11(1):49.CrossRef
Metadaten
Titel
Long-term test-retest of cerebral [18F]MK-6240 binding and longitudinal evaluation of extracerebral tracer uptake in healthy controls and amnestic MCI patients
verfasst von
Greet Vanderlinden
Nathalie Mertens
Laura Michiels
Robin Lemmens
Michel Koole
Mathieu Vandenbulcke
Koen Van Laere
Publikationsdatum
19.07.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 13/2022
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-022-05907-5

Weitere Artikel der Ausgabe 13/2022

European Journal of Nuclear Medicine and Molecular Imaging 13/2022 Zur Ausgabe